In 28 patients with r/r NKTCL, the anti-PD-1 monoclonal antibody sintilimab monotherapy showed a 2-year overall survival (OS) rate of 78.6% and an ORR of 75.0% in the phase 2 single-arm ORIENT-4 study (104). The gene discussed is PDCD1; the disease is extranodal nasal NK/T cell lymphoma.